Alkermes plc. Finite-Lived Intangible Assets, Gross
Alkermes plc. (ALKS) had Finite-Lived Intangible Assets, Gross of $1.00 million as of 2025-12-31, per its 10-Q filed 2026-07-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsGross · last filed 2026-07-28
- 2025-12-31: Finite-Lived Intangible Assets, Gross $1.00M; Finite-Lived Intangible Assets, Gross as first filed $583.75M.
- 2024-12-31: Finite-Lived Intangible Assets, Gross $583.75M.
- 2024-09-30: Finite-Lived Intangible Assets, Gross $583.75M.
- 2024-06-30: Finite-Lived Intangible Assets, Gross $583.75M.
| Period end | Finite-Lived Intangible Assets, Gross | Finite-Lived Intangible Assets, Gross as first filed |
|---|---|---|
| 2025-12-31 | $1.00M 10-Q · filed 2026-07-28 | $583.75M 10-K · filed 2026-02-25 |
| 2024-12-31 | $583.75M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $583.75M 10-Q · filed 2024-10-24 | |
| 2024-06-30 | $583.75M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $583.75M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $583.75M 10-K · filed 2025-02-12 | |
| 2023-09-30 | $583.75M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $583.75M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $583.75M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $583.75M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $583.75M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $583.75M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $583.75M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $583.75M 10-K · filed 2023-02-16 | |
| 2021-09-30 | $583.75M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $583.75M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $582.75M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $582.75M 10-K · filed 2022-02-16 | |
| 2020-09-30 | $582.75M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $582.75M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $582.75M 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $582.75M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $582.75M 10-Q · filed 2019-10-23 | |
| 2019-06-30 | $582.75M 10-Q · filed 2019-07-25 | |
| 2019-03-31 | $582.75M 10-Q · filed 2019-04-25 | |
| 2018-12-31 | $582.75M 10-K · filed 2020-02-13 | |
| 2018-09-30 | $582.75M 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $582.75M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $582.75M 10-Q · filed 2018-04-26 | |
| 2017-12-31 | $582.75M 10-K · filed 2019-02-15 | |
| 2017-09-30 | $582.75M 10-Q · filed 2017-10-26 | |
| 2017-06-30 | $582.75M 10-Q · filed 2017-07-27 | |
| 2017-03-31 | $582.75M 10-Q · filed 2017-04-27 | |
| 2016-12-31 | $582.75M 10-K · filed 2018-02-16 | |
| 2016-09-30 | $582.75M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $582.75M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $582.75M 10-Q · filed 2016-04-28 | |
| 2015-12-31 | $582.75M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $582.75M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $582.75M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $640.60M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $640.60M 10-K · filed 2016-02-25 | |
| 2014-09-30 | $640.60M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $640.60M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $640.60M 10-Q · filed 2014-04-30 | |
| 2013-12-31 | $640.60M 10-K · filed 2015-02-24 | |
| 2013-09-30 | $640.60M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $640.60M 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $640.60M 10-KT · filed 2014-02-27 | |
| 2012-12-31 | $640.60M 10-Q · filed 2013-01-31 | |
| 2012-09-30 | $640.60M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $640.60M 10-Q · filed 2012-07-26 | |
| 2012-03-31 | $643.20M 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |